Aug 14, 2023 | Press Releases
– Topline data for global pivotal Phase 3 RECOVER trial for brilaroxazine in schizophrenia expected in October 2023 – – Completion of 1-year open-label extension clinical trial for brilaroxazine in schizophrenia expected in Q3 2024 – CUPERTINO,...
Jul 31, 2023 | Press Releases
CUPERTINO, Calif., July 31, 2023 — Reviva Pharmaceuticals Holdings, Inc. (NASDAQ: RVPH) (“Reviva” or the “Company”), a clinical-stage pharmaceutical company developing therapies that seek to address unmet medical needs in the areas of...
Jun 26, 2023 | Press Releases
CUPERTINO, Calif., June 26, 2023 — Reviva Pharmaceuticals Holdings, Inc. (NASDAQ: RVPH) (“Reviva” or the “Company”), a clinical-stage pharmaceutical company developing therapies that seek to address unmet medical needs in the areas of...
Jun 22, 2023 | Press Releases
– Enrollment ongoing at multiple sites in the US, Europe, and Asia – – Multifaceted activity of serotonin-dopamine stabilizer brilaroxazine supports potential for improvement in schizophrenia symptoms as well as accompanying neuroinflammation –...
Jun 15, 2023 | Press Releases
CUPERTINO, Calif., June 15, 2023 — Reviva Pharmaceuticals Holdings, Inc. (NASDAQ: RVPH) (“Reviva” or the “Company”), a clinical-stage pharmaceutical company developing therapies that seek to address unmet medical needs in the areas of...
May 25, 2023 | Press Releases
Brilaroxazine, a novel serotonin-dopamine modulator with multifaceted activities has the potential to treat idiopathic pulmonary fibrosis (IPF) Brilaroxazine improved survival and lung function, and reduced lung fibrosis and inflammation in a bleomycin-induced rodent...
